64364-50-7

Usage

Uses

Used in Pharmaceutical Industry:
(2R,4S,5R,6R)-5-acetamido-2-[[(2R,3S,4S,5R,6S)-6-[(2R,3S,4R,5R,6R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxy-oxan-2-yl]methoxy]-4-hydroxy-6-[(1S,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is used as a potential pharmaceutical compound for its unique structure and properties. Its high polarity, hydrogen bonding potential, and the presence of carboxylic acid and carboxamide moieties make it a promising candidate for drug development, particularly in the areas of cell signaling, immune response, and metabolism.
Used in Biochemical Research:
In the field of biochemical research, (2R,4S,5R,6R)-5-acetamido-2-[[(2R,3S,4S,5R,6S)-6-[(2R,3S,4R,5R,6R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxy-oxan-2-yl]methoxy]-4-hydroxy-6-[(1S,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid can be utilized as a research tool to study the interactions between biomolecules and the role of complex carbohydrates and amino acids in biological processes. Its unique structure and properties may provide valuable insights into the development of new therapeutic agents and understanding the underlying mechanisms of various diseases.
Used in Drug Delivery Systems:
(2R,4S,5R,6R)-5-acetamido-2-[[(2R,3S,4S,5R,6S)-6-[(2R,3S,4R,5R,6R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxy-oxan-2-yl]methoxy]-4-hydroxy-6-[(1S,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid can be employed in the development of drug delivery systems, taking advantage of its high polarity, hydrogen bonding potential, and the presence of carboxylic acid and carboxamide moieties. These properties may enable the design of novel drug carriers that can improve the delivery, bioavailability, and therapeutic outcomes of various pharmaceutical agents.

Upstream product

• 81243-72-3 Benzyl-3,6-di-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2-azido-2-desoxy-β-D-glucopyranosid 
• 85750-98-7 Benzyl-2-azido-3,6-di-O-benzyl-2-desoxy-4-O-(2,3-di-O-benzyl-β-D-galactopyranosyl)-β-D-glucopyranosid 
• 85750-97-6 Benzyl-2-azido-3,6-di-O-benzyl-2-desoxy-4-O-(2,3-di-O-benzyl-4,6-O-benzyliden-β-D-galactopyranosyl)-β-D-glucopyranosid 
• 4307-58-8 N-acetyl-D-lactosamine 
• 108740-39-2 (1S,2R)-1-((2R,3R,4S,6R)-3-acetamido-4,6-diacetoxy-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)propane-1,2,3-triyl triacetate 
• 89733-63-1 Benzyl-O-(methyl-(5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-didesoxy-D-glycero-β-D-galacto-2-nonulopyranosyl)onat)-(2->6)-O-(2,3-di-O-benzyl-β-D-galactopyranosyl)-(1->4)-2-amino-3,6-di-O-benzyl-2-desoxy-β-D-glucopyranosid-dihydrogensulfid 
• 89733-64-2 Benzyl-O-(methyl-(5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-didesoxy-D-glycero-β-D-galacto-2-nonulopyranosyl)onat)-(2->6)-O-(4-O-acetyl-2,3-di-O-benzyl-β-D-galactopyranosyl)-(1->4)-2-acetamido-3,6-di-O-benzyl-2-desoxy-β-D-glucopyranosid 
• 67670-69-3 N-acetyl-4,7,8,9-tetra-O-acetyl-2-chloro-2-deoxyneuraminic acid methyl ester 
• 19342-36-0 2,4,7,8,9-Penta-O-acetyl-N-acetyl-β-D-neuraminsaeure 
• 89733-66-4 Benzyl-O-(5-acetamido-3,5-didesoxy-D-glycero-β-D-galacto-2-nonulopyranosylonsaeure)-(2->6)-O-(2,3-di-O-benzyl-β-D-galactopyranosyl)-(1->4)-2-acetamido-3,6-di-O-benzyl-2-desoxy-β-D-glucopyranosid 
• 85750-96-5 Benzyl-2-azido-4-O-(4,6-O-benzyliden-β-D-galactopyranosyl)-2-desoxy-β-D-glucopyranosid 
• 81243-73-4 benzyl 2-azido-2-deoxy-4-O-(β-D-galactopyranosyl)-β-D-glucopyranoside 
• 68733-24-4 O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1->4)-3,6-di-O-acetyl-2-azido-2-deoxy-α-D-glucopyranosyl bromide 
• 67670-69-3 methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-β-D-galacto-2-nonulopyranosylonate chloride 

Relevant academic research and scientific papers

A novel three-enzyme reaction cycle for the synthesis of N-acetyllactosamine with in situ regeneration of uridine 5'-diphosphate glucose and uridine 5'-diphosphate galactose

A new three-enzyme reaction cycle consisting of sucrose synthase, UDP glucose 4'-epimerase, and human β-1,4-galactosyltransferase was established for the synthesis of N-acetyllactosamine (LacNAc) with in situ regeneration of UDP galactose. We found that UDP glucose 4'-epimerase is reductively inactivated in the presence of UMP and acceptor substrates of β-1,4-galactosyltransferase. Reactivation of UDP glucose 4'-epimerase by the transition state analogues dUDP or dTDP 6-deoxy-D-xylo-4-hexulose in combination with the repetitive batch technique enabled us to use the native enzymes for 11 days in this cycle. With 10 U of sucrose synthase, 5 U of UDP glucose 4'-epimerase, and 1.25 U of β-1,4-galactosyltransferase, 594 mg of LacNAc could be synthesized. N-Acetyllactosamine was also subsequently converted to Neu5Acα2,6Ga1β1,4GlcNAc with α-2,6-sialyltransferase and CMP-Neu5Ac.

SYNTHESE EINES TRISACCHARIDES AUS N-ACETYLNEURAMINSAEURE UND N-ACETYLLACTOSAMIN

The reaction of methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2-chloro-2,3,5-trideoxy-D-glycero-β-D-galacto-2-nonulopyranosonate with benzyl 2-azido-3,6-di-O-benzyl-2-deoxy-4-O-(2,3-di-O-benzyl-β-D-galactopyranosyl)-β-D-glucopyranoside in the presence of mercury cyanide-mercuri bromide gave a 1:1 mixture of the two anomeric (2->6)linked trisaccharides containing N-acetylneuraminic acid.By chromatography, 22percent of benzyl O-(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonate)-(2->6)-O-(2,3-di-O-benzyl-β-D-galactopyranosyl)-(1->4)-2-azido-3,6-di-O-benzyl-2-deoxy-β-D-glucopyranoside and 23percent of the corresponding β-(2->6)-linked isomer could be isolated.A deblocking sequence, consisting of hydrogen sulfide reduction, acetylation, deacetylation, ester hydrolysis and hydrogenolysis led to the deblocked O-(5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2->6)-O-β-D-galactopyranosyl-(1->4)-2-acetamido-2-deoxy-D-glucopyranose and to the corresponding β-(2->6)-linked compound.